| 24001 |
Liraglutide |
Saxenda® |
Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg* |
Rapid Review Complete |
9th February 2024 |
 |
| 19039 |
Liraglutide |
Saxenda® |
As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is, as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease. |
Assessment process complete |
10th February 2021 |
|
| - |
Liraglutide |
Victoza® |
For treatment of adults with type 2 diabetes mellitus. |
Assessment process complete |
7th March 2019 |
|
| - |
Lisdexamfetamine dimesylate |
Tyvense® |
For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. |
Rapid Review Complete |
28th February 2013 |
|
| __ |
__ |
__ |
__ |
__ |
7th August 2014 |
|
| - |
Lomitapide |
Lojuxta® |
As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). |
Rapid Review Complete |
15th September 2014 |
|
| 23053 |
Loncastuximab tesirine |
Zynlonta® |
Loncastuximab tesirine (Zynlonta®) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. |
Rapid Review Complete |
1st September 2023 |
|
| - |
Lorlatinib |
Lorviqua® |
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on: (i) alectinib or ceritinib as the first ALK-targeted treatment, or (ii) crizotinib and at least one other ALK-targeted treatment. |
Rapid Review Complete |
25th June 2019 |
|
| 21071 |
Lorlatinib |
Lorviqua® |
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. |
Rapid Review Complete |
13th January 2022 |
|
| - |
Lornoxicam |
Xefo® |
For the short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis |
Rapid Review Complete |
7th July 2011 |
|
| - |
Loteprednol |
Lotemax 0.5% eye drops suspension |
For treatment of post-operative inflammation following ocular surgery. |
Rapid Review Complete |
5th December 2011 |
|
| - |
Loxapine inhalation powder |
Adasuve® |
For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. |
Rapid Review Complete |
28th July 2016 |
|
| - |
Lumacaftor/ivacaftor |
Orkambi® |
For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. |
Assessment process complete |
14th March 2024 |
|
| - |
Lutetium (177Lu) Oxodotreotide |
Lutathera® |
For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. |
Assessment process complete |
11th February 2020 |
|
| 23002 |
Lutetium (177Lu) vipivotide tetraxetan |
Pluvicto® |
Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. |
NCPE Assessment Process Complete |
12th August 2024 |
|
| 22062 |
Macimorelin acetate |
Ghryvelin® |
For the diagnosis of growth hormone deficiency (GHD) in adults. |
Rapid Review Complete |
20th October 2023 |
|
| - |
Macitentan |
Opsumit® |
Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. |
Rapid Review Complete |
31st January 2014 |
|
| 25009 |
Macitentan plus tadalafil |
Yuvanci® |
Macitentan plus tadalafil (Yuvanci®) is indicated as substitution therapy for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, who are already treated with the combination of macitentan and tadalafil given concurrently as separate tablets. |
Rapid Review Complete |
11th March 2025 |
|
| - |
Magnesium Aspartate Dihydrate |
Magnaspartate® |
For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years. |
Rapid Review Complete |
14th May 2019 |
|
| - |
Mannitol Dry Powder |
Bronchitol® |
Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF) |
Assessment Process Complete |
29th April 2019 |
|
| 25001 |
Maralixibat |
Livmarli® |
Maralixibat (Livmarli®) is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. |
Pre submission consultation scheduled |
4th February 2025 |
|
| 22069 |
Maribavir |
Livtencity® |
For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant. |
Rapid Review Complete |
14th March 2024 |
|
| 23028 |
Mavacamten |
Camzyos® |
Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. |
NCPE Assessment Process Complete |
20th January 2025 |
|
| - |
Melatonin |
Circadin® |
Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia. |
Full HTA Assessment |
21st October 2008 |
|
| 22048 |
Melatonin |
Slenyto® |
For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. |
Rapid Review Complete |
9th August 2022 |
|
| 23067 |
Melphalan flufenamide |
Pepaxti® |
Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation. |
Rapid Review Complete |
15th December 2023 |
|
| 25028 |
Melphalan flufenamide |
Pepaxti® |
Melphalan flufenamide in combination with dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation. |
Rapid Review Complete |
12th May 2025 |
|
| - |
Mepolizumab |
Nucala® |
Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. |
Assessment Process Complete |
1st March 2017 |
|
| - |
Mepolizumab |
Nucala® |
Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over. |
Rapid Review Complete |
5th November 2019 |
|
| 20007 |
Meropenem/vaborbactam |
Vaborem® |
Is indicated for the treatment of the above infections in adults. |
Rapid Review Complete |
2nd April 2020 |
|
| - |
Methoxyflurane |
Penthrox® |
For the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses. |
Rapid Review Complete |
18th December 2015 |
|
| 19049 |
Methyl aminolevulinate |
Metvix® |
For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate. |
Rapid Review Complete |
18th December 2019 |
|
| - |
Midostaurin |
Rydapt® |
Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. |
Assessment Process Complete |
5th December 2019 |
|
| - |
Midostaurin |
Rydapt® |
Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). |
Suspended |
16th October 2018 |
|
| - |
Mifamurtide |
Mepact® |
For the treatment of osteosarcoma. |
Rapid Review Complete |
13th July 2010 |
|
| - |
Migalastat |
Galafold® |
For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. |
Assessment Process Complete |
1st June 2017 |
|
| - |
Mirabegron |
Betmiga® |
Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. |
Rapid Review Complete |
12th March 2013 |
|
| 23040 |
Mirikizumab |
Omvoh® |
Mirikizumab (Omvoh®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. |
Rapid Review Complete |
24th August 2023 |
|
| 24051 |
Mirvetuximab |
Elahere® |
Mirvetuximab soravtansine (Elahere®) is indicated as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. |
Pre submission consultation scheduled |
4th February 2025 |
|
| - |
Modified Release Hydrocortisone |
Plenadren® |
For the treatment of adrenal insufficiency in adults. |
Assessment process complete |
1st January 2018 |
|
| 20061 |
Mogamulizumab |
Poteligeo® |
For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 21060 |
Molnupiravir |
Lagevrio® |
For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
Rapid Review Complete |
24th December 2021 |
|
| 24002 |
Momelotinib |
Omjjara® |
Momelotinib (Omjjara®) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. |
Rapid Review Complete |
22nd February 2024 |
|
| 21051 |
Mometasone furoate plus olopatadine |
Ryaltris® |
Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older. |
Rapid Review Complete |
22nd December 2021 |
|
| 23023 |
Mosunetuzumab |
Lunsumio® |
Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. |
NCPE Assessment Process Complete |
24th March 2025 |
|
| - |
Nab-paclitaxel |
Abraxane® |
In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas. |
Assessment Process Complete |
5th September 2014 |
|
| - |
Nalmefene |
Selincro® |
Is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification. |
Assessment Process Complete |
8th April 2014 |
|
| - |
Naloxegel |
Moventig® |
Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). |
Rapid Review Complete |
13th April 2015 |
|
| 20019 |
Naloxone |
Nyxoid® |
Intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care. |
Rapid Review Complete |
12th May 2020 |
|
| - |
Naltrexone / bupropion |
Mysimba® |
Is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities. |
Assessment Process Complete |
9th May 2018 |
|
